Company: BIVIW
Filing Date: 2025-07-11
Form Type: S-1/A
Source: 0001520138-25-000205
Chunk: 46

Company: BIOVIE INC.
Filing Date: 2025-07-11
Form: S-1/A
Chunk 46
---
 produce patents that would materially and adversely affect our business, prospects, financial condition
and results of operations, in which event you could lose all of your investment.

We may enter into licensing and collaboration agreements with third parties. If we fail to comply with our obligations in the agreements under which we license intellectual property rights to or from third parties, or these agreements are terminated, or we otherwise experience disruptions to our business relationships with our licensors or licensees, our competitive position, business, financial condition, results of operations and prospects could be harmed.

It may be necessary for us to use the patented
or proprietary technology of third parties to commercialize our products (if approved), in which case we would be required to obtain a
license from these third parties. The licensing of third-party intellectual property rights is a competitive area, and more established
companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary.
More established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development
and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights
to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate
return on our investment or at all. If we are unable to license such technology, or if we are forced to license such technology on unfavorable
terms, our business could be materially harmed.

We may fail to obtain any of these licenses or
intellectual property rights on commercially reasonable terms. Even if we are able to obtain a license, it may be non-exclusive, thereby
giving our competitors access to the same technologies licensed to us. Licenses may not provide us with exclusive rights to use the applicable
intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize
our drug candidates, products (if approved) and technology in the future. In that event, we may be required to expend significant time
and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the
affected products, which could materially harm our business and the third parties owning such intellectual property rights could seek
either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms
of compensation. Conversely, we may not always be able to successfully pursue